CN102532213A - Method for preparing ribostamycin rough products by using membrane separation technology - Google Patents
Method for preparing ribostamycin rough products by using membrane separation technology Download PDFInfo
- Publication number
- CN102532213A CN102532213A CN2011104497467A CN201110449746A CN102532213A CN 102532213 A CN102532213 A CN 102532213A CN 2011104497467 A CN2011104497467 A CN 2011104497467A CN 201110449746 A CN201110449746 A CN 201110449746A CN 102532213 A CN102532213 A CN 102532213A
- Authority
- CN
- China
- Prior art keywords
- membrane
- ribostamycin
- liquid
- bullion
- separation technique
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 82
- NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229930190553 ribostamycin Natural products 0.000 title claims abstract description 51
- NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 title claims abstract description 51
- 229960003485 ribostamycin Drugs 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000000926 separation method Methods 0.000 title claims abstract description 29
- 238000005516 engineering process Methods 0.000 title abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 53
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 26
- 239000012535 impurity Substances 0.000 claims abstract description 17
- 238000010612 desalination reaction Methods 0.000 claims abstract description 15
- 150000004676 glycans Chemical class 0.000 claims abstract description 8
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 8
- 239000005017 polysaccharide Substances 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- -1 coloring matters Substances 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims abstract 2
- 238000001471 micro-filtration Methods 0.000 claims description 19
- 230000004907 flux Effects 0.000 claims description 15
- 239000002131 composite material Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 239000004760 aramid Substances 0.000 claims description 6
- 229920003235 aromatic polyamide Polymers 0.000 claims description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000956 alloy Substances 0.000 claims description 3
- 229910045601 alloy Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000007769 metal material Substances 0.000 claims description 3
- 229920002492 poly(sulfone) Polymers 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 229910010293 ceramic material Inorganic materials 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000010413 mother solution Substances 0.000 claims 1
- 239000012466 permeate Substances 0.000 claims 1
- 238000001728 nano-filtration Methods 0.000 abstract description 10
- 238000000605 extraction Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 238000004040 coloring Methods 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000010408 film Substances 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- 235000014666 liquid concentrate Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- RTCDDYYZMGGHOE-YMSVYGIHSA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](N)C[C@@H]1N RTCDDYYZMGGHOE-YMSVYGIHSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003311 flocculating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical class FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 206010061695 Biliary tract infection Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
The invention provides a method for preparing ribostamycin rough products by using membrane separation technology. The method comprises the steps of micro filter membrane edulcoration of feed liquid, ultrafiltration decoloration and nanofiltration desalination, enrichment, concentration and drying in a preparation process of the ribostamycin rough products. The feed liquid containing ribostamycin is carried out liquid and solid separation of micro filter membrane, protein micro filter permeating liquid, coloring matters, polysaccharide and other macromolecule impurities are removed through the ultrafiltration membrane, collected permeating liquid is desalted and enriched under normal temperature through the permeating liquid, and the desalt liquid is concentrated and dried to manufacture the ribostamycin rough products. The method for preparing ribostamycin rough products by using the membrane separation technology is novel in conception, mild in productive technology conditions, environment-friendly and clean, simple and easy to do, short in production cycle, low in production cost, high in extraction yield and strong in application, and has big application and dissemination values.
Description
Technical field
The present invention relates to a kind of aminoglycoside antibiotics ribostamycin separation of produced method, be specially and relate to a kind of method that adopts membrane separation technique separation of produced ribostamycin.
Background technology
Ribostamycin is a kind of Broad spectrum antibiotics, and is effective to the Bacillus proteus bacterial strain of staphylococcus, suis, streptococcus pneumoniae, pneumobacillus, intestinal bacteria and part.Be applicable to the various severe infections that responsive enterobacteriaceae lactobacteriaceae such as escherichia coli, klebsiella spp, proteus, Shigella etc. cause clinically, like respiratory tract, abdominal cavity, thoracic cavity, urinary tract, skin and soft tissue, osseous tissue and eye, ear, nose infection due to pneumonia, septicemia, biliary tract infection and the responsive gram negative bacillus.Compare with other aminoglycoside antibioticss such as kantlex etc., toxicity is lower, and is all less to the toxicity of the sense of hearing and kidney, is its main advantage.Common many and wide spectrum semi-synthetic penicillins, cephalosporins or other antibacterials combined utilization.
Therefore, develop a kind of ribostamycin separation of produced method of efficient energy-saving, have good market outlook and social benefit.
Ribostamycin is to be that to produce bacterium, W-Gum, soybean cake powder be that main raw material is cultivated the secondary metabolite that obtains through submerged fermentation with actinomycetes.The ribostamycin extraction preparation method mainly adopts plate-and-frame filter press press filtration, filtrating directly to drop into the separation and Extraction that fermented liquid carries out Static Adsorption, realizes ribostamycin through ion exchange resin dynamic adsorption or ion exchange resin at present.
The technology weak point is at present: the dynamic adsorption process, even add flocculating aids, the still more sad filter of fermented liquid in the fermented liquid Plate Filtration process; Filtration velocity is slow; Filter pressure is up to 0.4-0.6Mpa, and filter cake is shapeless, feed liquid is lost, it is on the low side to filter yield, and labour intensity is big; And the Static Adsorption process, ion exchange resin with fermented liquid in the residue sepn process in, situation such as it is serious that ion exchange resin runs off, and the low and contaminated wastewater of yield is more serious.
Summary of the invention
The present invention provides a kind of method that adopts membrane separation technique to prepare the ribostamycin bullion.The ribostamycin fermented liquid is handled through microfiltration membrane, removes a large amount of thalline, bacterial chip, high molecular weight protein and fermented liquid residues in the fermented liquid, obtains the clarification micro-filtration and sees through liquid; Micro-filtration sees through liquid and further removes macromole impurity such as deproteinize, pigment and polysaccharide through ultra-filtration membrane, and the ultrafiltration of collection sees through liquid and carries out normal temperature desalination, enrichment through nf membrane; Demineralised liquid becomes the about 8-15Be of concentration ° liquid concentrator through thin film concentration, supplies further purification production ribostamin or liquid concentrator to make the ribostamycin bullion through centrifugal spray drying and supplies the refining ribostamin of producing.The present invention has alleviated productive labor intensity, has improved the recovery of separation and Extraction, has reduced the quantity discharged of acidic and alkaline waste water.
The concrete parameter and the process characteristic of the microfiltration membrane of the separation and Extraction ribostamycin that the present invention adopts, ultra-filtration membrane, nf membrane are following:
1. select for use molecular weight cut-off to be 30000-500000, preferentially to select the microfiltering separation film of 50000-100000; At the microfiltration membrane flux is 30L/h ㎡～50L/h ㎡, and working pressure is through micro-filtration separation of mycelial, culture medium residue etc. under the operational condition of 5 ℃～35 ℃ of 1.0 bar-3.5bar, service temperature;
2. selecting molecular weight cut-off for use is 5000～100000 ultra-filtration and separation film; At the ultra-filtration membrane flux is 30L/h ㎡～45 L/h ㎡; Working pressure is 1.0 bar～6.0bar; Through the ultrafiltration removal of impurities, remove macromole impurity such as protein, polysaccharide and colour former under the operational condition that service temperature is 5 ℃～35 ℃;
3. it is 300～800 nanofiltration separation membrane that nf membrane desalination, enrichment process are selected molecular weight cut-off for use; It is 20L/h ㎡～40 L/h ㎡ at the nf membrane flux that ultrafiltration sees through liquid; Working pressure is 6.0 bar～12.0bar; Under the operational condition that service temperature is 5 ℃～35 ℃, through nanofiltration desalination, enrichment 3～5 times, the volume of demineralised liquid is about the 20-30% of filtrating;
4. the mould material of microfiltration membrane separating thallus, residue process can be one or more and combination of inorganic ceramic material, metal, alloy and other non-metallic material, preferentially selects stupalith for use;
5. the mould material of ultra-filtration membrane removal of impurities, decolorization can be one or more in inorganic ceramic class, polysulfones, polyvinylidene difluoride, aromatic polyamides class, FM class, the composite package class mould material; Preferentially select composite package class, polysulfones, polyvinylidene difluoride, aromatic polyamides class for use; The membrane module type of said ultra-filtration membrane can be tubular type, tubular fibre, rolling, plate and frame, preferentially selects rolled film for use;
6. the mould material of nanofiltration desalination, concentration process can be one or more in polyvinylidene difluoride, aromatic polyamides class, FM class, the composite package class mould material, preferentially selects composite package class, vinylidene fluoride class, aromatic polyamides class for use; The membrane module type of said nf membrane can be tubular type, rolling, plate and frame, preferentially selects rolled film for use.
Compare with existing Technology, the present invention has outstanding feature:
1. present method not only helps containing feed liquid removal of impurities, separation, desalination, the enrichment of ribostamycin, and has got rid of the required heavy process such as sheet frame operation of dynamic adsorption technology;
2. present method benefit feed liquid of being to avoid Static Adsorption causes in the ribostamycin leaching process resin drift or Plate Filtration to cause caused yield that runs off descends;
3. present method benefit is that technology is simple, the energy consumption material consumption is low, green cleaning, be convenient to implement, and the activity duration is short, reduced add that flocculating aids causes secondary pollution etc., improved the quality of product.
Embodiment
Adopt membrane separation technique to prepare the method for ribostamycin liquid concentrator or ribostamycin bullion in order better to set forth the present invention, below the present invention is described further, but do not limit the present invention in any way through specific embodiment.
Embodiment 1
To contain ribostamycin concentration is that the fermented liquid 260L of 5.5g/L is a raw material, and adopting molecular weight cut-off is 50000 ceramic microfiltration membrane, is 35L/h ㎡ at flux, and working pressure is 2.5bar, removes fermented liquid thalline and residue under the operational condition that service temperature is 35 ℃.Seeing through liquid, to adopt molecular weight cut-off be 5000 composite hyperfiltration membrane, is 30 L/h ㎡ at membrane flux, and working pressure is 5.0bar, through the ultra-filtration membrane removal of impurities, removes protein, polysaccharide and colour former etc. under the operational condition that service temperature is 30 ℃.Ultrafiltration sees through liquid, and to adopt molecular weight cut-off be that 300 composite package carries out nanofiltration and handles; At the nf membrane flux is 30 L/h ㎡; Working pressure is 10.0bar; Under the operational condition that service temperature is 30 ℃, through 3 nanofiltration desalinations, enrichment, demineralised liquid concentrates, is spray dried to ribostamycin off-white color bullion through film under vacuum.Through measuring the ribostamycin recovery is 96.2%, and ribostamycin content is 83.8%.
Embodiment 2
To contain ribostamycin concentration is that the fermented liquid 350L of 5.0g/L is a raw material, and adopting molecular weight cut-off is 50000 ceramic microfiltration membrane, is 40L/h ㎡ at flux, and working pressure is 3.0bar, removes fermented liquid thalline and residue under the operational condition that service temperature is 30 ℃.Seeing through liquid, to adopt molecular weight cut-off be 5000 composite hyperfiltration membrane, is 30 L/h ㎡ at membrane flux, and working pressure is 5.0bar, through the ultra-filtration membrane removal of impurities, removes protein, polysaccharide and colour former etc. under the operational condition that service temperature is 30 ℃.Ultrafiltration sees through liquid, and to adopt molecular weight cut-off be that 300 composite package carries out nanofiltration and handles; At the nf membrane flux is 30 L/h ㎡; Working pressure is 8.0bar; Under the operational condition that service temperature is 30 ℃, through 4 nanofiltration desalinations, enrichment, demineralised liquid concentrates, is spray dried to ribostamycin off-white color bullion through film under vacuum.Through measuring the ribostamycin recovery is 94.6%, and ribostamycin content is 80.2%.
Embodiment 3
To contain ribostamycin concentration is that prostitute's mother liquor 35L of 98.0g/L is a raw material; Purified water is diluted to 350L, and to adopt molecular weight cut-off be 50000 ceramic microfiltration membrane; At flux is 40L h ㎡, and working pressure is 3.0bar, removes mother liquor impurity under the operational condition that service temperature is 30 ℃.Seeing through liquid, to adopt molecular weight cut-off be 5000 composite hyperfiltration membrane, is 30 L/h ㎡ at membrane flux, and working pressure is 5.0bar, through the ultra-filtration membrane removal of impurities, removes colour former etc. under the operational condition that service temperature is 30 ℃.Ultrafiltration sees through liquid, and to adopt molecular weight cut-off be that 300 composite package carries out nanofiltration and handles; At the nf membrane flux is 30 L/h ㎡; Working pressure is 10.0bar; Under the operational condition that service temperature is 30 ℃, through 5 nanofiltration desalinations, enrichment, demineralised liquid concentrates, is spray dried to ribostamycin off-white color bullion through film under vacuum.Through measuring the ribostamycin recovery is 96.8%, and ribostamycin content is 82.5%.
Claims (10)
1. method that adopts membrane separation technique to prepare the ribostamycin bullion; Be primarily characterized in that and comprise microfiltration membrane removal mycelium, fermented liquid residue; Ultra-filtration membrane removal of impurities, decolouring and nf membrane desalination, enrichment; Concentrated, exsiccant step: the feed liquid that contains ribostamycin is handled through microfiltration membrane, removes mycelium, fermented liquid residue; Micro-filtration sees through liquid and removes macromole impurity such as protein, pigment and polysaccharide through ultra-filtration membrane; The ultrafiltration of collecting sees through liquid and carries out normal temperature desalination, enrichment through nf membrane, and demineralised liquid makes the ribostamycin bullion through concentrated, drying.
2. a kind of method that adopts membrane separation technique to prepare the ribostamycin bullion according to claim 1; It is characterized in that: with the feed liquid that contains ribostamycin is raw material; Under the working pressure of 1.5-3.5bar, remove impurity such as mycelium, culture medium residue through microfiltration membrane; Microfiltration membrane sees through liquid under 1.5～6.0bar working pressure condition, through macromole impurity such as ultra-filtration membrane decolouring, removal protein and polysaccharide; Ultrafiltration membrane permeate liquid is under 6.0～12bar working pressure condition, through nf membrane desalination, enrichment; Demineralised liquid is through concentrated, the dry ribostamycin bullion that obtains.
3. employing membrane separation technique according to claim 1 prepares the method for ribostamycin bullion, it is characterized in that: it is the separatory membrane of 30000-500000 that said microfiltration membrane separating thallus, residue process are selected molecular weight cut-off for use; It is 5000～30000 separatory membrane that ultra-filtration membrane removal of impurities process is selected molecular weight cut-off for use; It is 300～800 separatory membrane that nf membrane desalination, enrichment process are selected molecular weight cut-off for use.
4. employing membrane separation technique according to claim 1 prepares the method for ribostamycin bullion, it is characterized in that: the mould material of said microfiltration membrane separating thallus, residue process is one or more and combination of inorganic ceramic material, metal, alloy and other non-metallic material.
5. employing membrane separation technique according to claim 1 prepares the method for ribostamycin bullion, it is characterized in that: the mould material of macromole impurity processes such as ultra-filtration membrane decolouring, removal protein and polysaccharide is one or more in inorganic (containing stupalith, metal, alloy and other non-metallic material) class, polysulfones, polyvinylidene difluoride, aromatic polyamides class, FM class, the composite package class mould material.
6. employing membrane separation technique according to claim 1 prepares the method for ribostamycin bullion, it is characterized in that: the mould material in said nf membrane desalination, the concentration process is one or more in polyvinylidene difluoride, aromatic polyamides class, FM class, the composite package class mould material.
7. employing membrane separation technique according to claim 1 prepares the method for ribostamycin bullion, it is characterized in that: the membrane module type of said microfiltration membrane, ultra-filtration membrane, nf membrane is one or more in tubular type, tubular fibre, rolling, the plate and frame.
8. employing membrane separation technique according to claim 1 prepares the method for ribostamycin bullion, it is characterized in that: the membrane flux that said microfiltration membrane is removed thalline, residue process is 30-50L/h ㎡, 5 ℃～35 ℃ of service temperatures; The membrane flux of ultra-filtration membrane decolouring, removal of impurities process is 30L/h ㎡～45 L/h ㎡, 5 ℃～35 ℃ of service temperatures; The membrane flux of nf membrane desalination, enrichment process is 20L/h ㎡～40 L/h ㎡, 5 ℃～35 ℃ of service temperatures.
9. employing membrane separation technique according to claim 1 prepares the method for ribostamycin bullion, it is characterized in that: said feed liquid is the fermented liquid that contains the ribostamycin composition, ferment filtrate, liquid concentrator, sees through liquid, crystalline mother solution, recovery liquid etc.
10. employing membrane separation technique according to claim 1 prepares the method for ribostamycin bullion, it is characterized in that: said ribostamycin bullion is to contain the liquid liquid concentrator of ribostamycin content >=70%, solid-state bullion etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104497467A CN102532213A (en) | 2011-12-29 | 2011-12-29 | Method for preparing ribostamycin rough products by using membrane separation technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104497467A CN102532213A (en) | 2011-12-29 | 2011-12-29 | Method for preparing ribostamycin rough products by using membrane separation technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102532213A true CN102532213A (en) | 2012-07-04 |
Family
ID=46340370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104497467A Pending CN102532213A (en) | 2011-12-29 | 2011-12-29 | Method for preparing ribostamycin rough products by using membrane separation technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102532213A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106554374A (en) * | 2016-11-29 | 2017-04-05 | 无锡福祈制药有限公司 | A kind of method that purification prepares vistamycin in fermentation liquid from ribostamycin |
| CN108148100A (en) * | 2017-09-15 | 2018-06-12 | 江苏九天高科技股份有限公司 | The method of purification and device of a kind of oligosaccharide |
| CN110272461A (en) * | 2019-06-29 | 2019-09-24 | 赤峰蒙广生物科技有限公司 | A method of purifying beta-thymidine from fermentation liquid |
| CN111004298A (en) * | 2019-12-20 | 2020-04-14 | 无锡福祈制药有限公司 | Preparation method of high-purity ribostamycin sulfate |
| CN112851721A (en) * | 2021-01-21 | 2021-05-28 | 浙江新银象生物工程有限公司 | Method for recovering natamycin crystallization mother liquor |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008362A (en) * | 1972-08-25 | 1977-02-15 | Meiji Seika Kaisha, Ltd. | 1-N-((S)-α-substituted-ω-aminoacyl)-neamine or -ribostamycin and the production thereof |
| US4351830A (en) * | 1980-06-17 | 1982-09-28 | Meiji Seika Kaisha, Ltd. | Polymeric compound, MF-300, with protective activity against bacterial infections and its preparation |
| CN1974586A (en) * | 2006-12-20 | 2007-06-06 | 福州大学 | Aminoglycoside antibiotics enriching and purifying macroporous resin process |
| CN101861350A (en) * | 2007-08-20 | 2010-10-13 | 技术研究及发展基金有限公司 | Polysulfone polymers and membranes for reverse osmosis, nanofiltration and ultrafiltration |
-
2011
- 2011-12-29 CN CN2011104497467A patent/CN102532213A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008362A (en) * | 1972-08-25 | 1977-02-15 | Meiji Seika Kaisha, Ltd. | 1-N-((S)-α-substituted-ω-aminoacyl)-neamine or -ribostamycin and the production thereof |
| US4351830A (en) * | 1980-06-17 | 1982-09-28 | Meiji Seika Kaisha, Ltd. | Polymeric compound, MF-300, with protective activity against bacterial infections and its preparation |
| CN1974586A (en) * | 2006-12-20 | 2007-06-06 | 福州大学 | Aminoglycoside antibiotics enriching and purifying macroporous resin process |
| CN101861350A (en) * | 2007-08-20 | 2010-10-13 | 技术研究及发展基金有限公司 | Polysulfone polymers and membranes for reverse osmosis, nanofiltration and ultrafiltration |
Non-Patent Citations (4)
| Title |
|---|
| 崔丽娟，等: "膜分离技术在抗生素工业生产中的应用", 《食品与药品》, vol. 12, no. 5, 10 May 2010 (2010-05-10), pages 213 - 216 * |
| 王赟，等: "抗生素提取技术及研究进展", 《中国抗生素杂志》, vol. 34, no. 11, 30 November 2009 (2009-11-30), pages 641 - 648 * |
| 邬方宁: "膜分离技术在药物分离中的应用", 《天津药学》, vol. 22, no. 2, 28 April 2010 (2010-04-28), pages 65 - 69 * |
| 顾觉奋: "膜分离技术在微生物制药中的应用", 《中国抗生素杂志》, vol. 30, no. 1, 31 January 2005 (2005-01-31), pages 26 - 31 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106554374A (en) * | 2016-11-29 | 2017-04-05 | 无锡福祈制药有限公司 | A kind of method that purification prepares vistamycin in fermentation liquid from ribostamycin |
| CN106554374B (en) * | 2016-11-29 | 2018-11-27 | 无锡福祈制药有限公司 | A method of purification prepares vistamycin from ribostamycin fermentation liquid |
| CN108148100A (en) * | 2017-09-15 | 2018-06-12 | 江苏九天高科技股份有限公司 | The method of purification and device of a kind of oligosaccharide |
| CN108148100B (en) * | 2017-09-15 | 2023-06-06 | 江苏九天高科技股份有限公司 | Method and device for purifying oligosaccharide |
| CN110272461A (en) * | 2019-06-29 | 2019-09-24 | 赤峰蒙广生物科技有限公司 | A method of purifying beta-thymidine from fermentation liquid |
| CN110272461B (en) * | 2019-06-29 | 2022-09-06 | 赤峰蒙广生物科技有限公司 | Method for purifying beta-thymidine from fermentation liquor |
| CN111004298A (en) * | 2019-12-20 | 2020-04-14 | 无锡福祈制药有限公司 | Preparation method of high-purity ribostamycin sulfate |
| CN112851721A (en) * | 2021-01-21 | 2021-05-28 | 浙江新银象生物工程有限公司 | Method for recovering natamycin crystallization mother liquor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101475464A (en) | A method for separating and extracting succinic acid from succinic acid fermentation broth by nanofiltration | |
| CN102532213A (en) | Method for preparing ribostamycin rough products by using membrane separation technology | |
| RU2016128955A (en) | METHOD FOR EFFECTIVE CLEANING OF NEUTRAL HUMAN MILK OLIGOSACCHARIDES (HMO) OBTAINED BY MICROBIOLOGICAL FERMENTATION | |
| WO2010051676A1 (en) | A cleaning process of producing lactic acid | |
| CN211111802U (en) | Purification device of antibiotic zymotic fluid | |
| CN102040531B (en) | Method for extracting L-isoleucine | |
| JP2013514067A5 (en) | ||
| CN102978250B (en) | Method for producing Gamma-aminobutyric acid through centrifugal mother liquid of glutamic acid | |
| CN101654413A (en) | Method for extracting and separating L-isoleucine employing three-stage film cascade | |
| CN110272461B (en) | Method for purifying beta-thymidine from fermentation liquor | |
| CN105017360A (en) | Vitamin B12 preparation method | |
| CN101492408A (en) | Method for separating tryptophane from fermentation liquor | |
| CN109369730A (en) | Sialic acid and its extracting method | |
| CN102399248A (en) | Method for preparing paromomycin crude product by adopting membrane separation technology | |
| CN102391329B (en) | Method for preparing crude paromomycin with membrane separation technology | |
| CN104278071B (en) | The extracting method of cephalosporin | |
| CN103232362B (en) | Process for extracting L-glutamine | |
| CN105837488A (en) | Hydroxyproline fermentation production technology | |
| CN102838624A (en) | Method for purifying clavulanic acid from fermentation liquor | |
| CN101693732B (en) | Method for extracting and purifying natamycin | |
| CN101974075A (en) | Method for extracting polymyxin B and E from fermentation technique culture | |
| CN102351930B (en) | Method for separating spiramycin fermentation liquid by ceramic membrane microfiltration separation technique | |
| CN100487129C (en) | Clean production process of tetracycline antibiotics | |
| CN102432495B (en) | Method for separating and concentrating L-theanine from glutaminase or glutamyl transpeptidase conversion liquid by membrane integration technology | |
| CN206051902U (en) | A kind of capreomycin production system based on membrane technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120704 |